Four additional untried treatment solutions for the Ebola virus danger have received a green signal from the Democratic Republic of Congo as a move from the health ministry in its efforts to control the virus’ spread.
On July 6th, the health ministry of Congo announced that health workers in were setting up refrigerators for maintaining an Ebola vaccine under cold conditions in order to tackle an Ebola outbreak, which was believed to have affected an estimated 43 people.
WHO officials have not yet pinpointed the strain of Ebola that is responsible for the death of 20 people and has infected four more, including two health workers. They are uncertain whether it could be the Zaire, Sudan or Bundibugyo strain.
In the latest Ebola outbreak, a total of 61 cases were recorded and 28 lives were claimed in the Congo region. But now the World Health Organization has reported that the spread of this Ebola outbreak has "largely been contained" after the success of Merck's late-stage vaccination campaign for more than a month.
A new study was conducted by Paolo Bocchini, associate professor of civil and environmental engineering, Javier Buceta, an associate professor of bioengineering, and postdoctoral researcher Graziano Fiorillo. They were affiliated with the Lehigh University in Bethlehem, PA. They hypothesized that, since fruit bats carry the Ebola virus, tracking down their migratory patterns might give information about the time and location of the next outbreak.
As the Democratic Republic of Congo deals with a rising death toll owing to the latest outbreak of Ebola, health officials are moving fast to counter the fatal effects of the deadly virus. Plans are afoot to implement the experimental vaccine developed by Merck & Co to confront the overwhelming challenges posed by the virus.
The Government of the Democratic Republic of the Congo declared a new outbreak of Ebola virus disease (EVD) in Bikoro in Equateur Province today (8 May). The outbreak declaration occurred after laboratory results confirmed two cases of EVD.
After initially setting out to test two vaccines on 28,000 volunteers during West Africa's deadly Ebola epidemic, a U.S.-Liberia research team had to dramatically reduce its aspirations when the outbreak started coming to an end. But the investigators have now published results showing the shots from GlaxoSmithKline and Merck elicited antibody responses that lasted one year after vaccination.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.